EuGeni, page-2326

The release way back on 28/10/2021 mentions a USA 2022 EuGeni Entry. Though we now know the Sepsis project has been scaled to longer timeliness.

"In preparation for a US market entry with the EuGeni Reader, COVID-19 RAT, FluA/ FluB COVID-19 Multiplex and Sepsis in 2022, AnteoTech has appointed a US-based market entry and marketing consultant. These specialists have previously consulted with major companies, including Ellume, to navigate the US point of care and healthcare sectors successfully. The newly appointed Head of Product & Services, Pierre Nathie, will be working closely with our consultant, preparing the go-tomarket strategy, and identifying US-based distribution partners and agents. Entry into the US market is predicated on the successful registration of the products with the US Food and Drug Administration (FDA)."